We rank companies based on fund manager, research analyst and news sentiment
ANIP stock icon

ANI Pharmaceuticals
ANIP

$66.88
1.81%
 

About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Employees: 642

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 5 analysts
0
News positive %
of 8 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

416% more call options, than puts

Call options by funds: $1.25M | Put options by funds: $243K

1.54% more ownership

Funds ownership: 64.98% [Q3] → 66.53% (+1.54%) [Q4]

4% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 53

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

2% less capital invested

Capital invested by funds: $765M [Q3] → $749M (-$16.5M) [Q4]

2% less funds holding

Funds holding: 184 [Q3] → 180 (-4) [Q4]

11% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 35

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$72
8%
upside
Avg. target
$77
15%
upside
High target
$83
24%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Guggenheim
Vamil Divan
15%upside
$77
Buy
Maintained
5 Mar 2024
HC Wainwright & Co.
Oren Livnat
24%upside
$83
Buy
Maintained
4 Mar 2024
Truist Securities
Gregory Fraser
20%upside
$80
Buy
Maintained
1 Mar 2024
Truist Securities
Gregory Fraser
8%upside
$72
Buy
Maintained
16 Feb 2024
Guggenheim
Vamil Divan
8%upside
$72
Buy
Reiterated
19 Oct 2023

Financial journalist opinion

Based on 8 articles about ANIP published over the past 30 days